We are live on ! Find out more
MS

Maven Securities Portfolio holdings

AUM $5.2B
1-Year Est. Return 44.01%
This Fund
S&P 500
This Quarter Est. Return
+3.03%
1 Year Est. Return
+44.01%
3 Year Est. Return
+102.83%
5 Year Est. Return
+136.18%
10 Year Est. Return
–
AUM
$112M
AUM Growth
–
Cap. Flow
+$110M
Cap. Flow %
98.89%
Top 10 Hldgs %
87.78%
Holding
44
New
44
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
HSBC icon
HSBC
HSBC
+$32.2M
2
BTI icon
British American Tobacco
BTI
+$15.4M
3
CUK
Carnival PLC
CUK
+$11.7M
4
MON
Monsanto Co
MON
+$9.74M
5
BBL
BHP Group Plc American Depositary Shares (Each representing two Ordinary Shares)
BBL
+$8.45M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Financials 34.12%
2 Consumer Staples 17.37%
3 Consumer Discretionary 12.02%
4 Materials 8.95%
5 Communication Services 4.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVS icon
26
Novartis
NVS
$295B
$346K 0.31%
+5,302
New +$344K
DELL icon
27
Dell
DELL
$283B
$253K 0.23%
+164,828
New +$2.36M
SHPG
28
DELISTED
Shire pic
SHPG
$227K 0.2%
+1,312
New +$233K
XBI icon
29
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$140K 0.13%
+2,353
New +$145K
IL
30
DELISTED
IntraLinks Holdings Inc.
IL
$123K 0.11%
+9,178
New +$102K
TSM icon
31
TSMC
TSM
$2.09T
$87K 0.08%
+3,000
New +$90.3K
MSFT icon
32
Microsoft
MSFT
$2.84T
$73K 0.07%
+1,160
New +$69.8K
CELG
33
DELISTED
Celgene Corp
CELG
$69K 0.06%
+594
New +$66.2K
LYG icon
34
Lloyds Banking Group
LYG
$87.4B
$68K 0.06%
+22,032
New +$64.5K
INCY icon
35
Incyte
INCY
$23.5B
$67K 0.06%
+666
New +$65K
IONS icon
36
Ionis Pharmaceuticals
IONS
$9.35B
$57K 0.05%
+1,176
New +$46.5K
RDUS
37
DELISTED
Radius Health, Inc.
RDUS
$36K 0.03%
+935
New +$44.5K
GILD icon
38
Gilead Sciences
GILD
$161B
$34K 0.03%
+476
New +$35.4K
TEVA icon
39
Teva Pharmaceuticals
TEVA
$35.9B
$28K 0.03%
+776
New +$31K
ALXN
40
DELISTED
Alexion Pharmaceuticals
ALXN
$22K 0.02%
+177
New +$21.7K
AGIO icon
41
Agios Pharmaceuticals
AGIO
$2.16B
$21K 0.02%
+503
New +$26.4K
NBIX icon
42
Neurocrine Biosciences
NBIX
$17.7B
$21K 0.02%
+567
New +$25.7K
VRTX icon
43
Vertex Pharmaceuticals
VRTX
$121B
$16K 0.01%
+219
New +$17.8K
FGL
44
DELISTED
Fidelity & Guaranty Life
FGL
$12K 0.01%
+500
New +$11.6K
1
2

Similar funds

AUB
Atlantic Union Bankshares Glen Allen, Virginia $5.21B AUM 19.46% 1-Year Est. Return
AP
Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return
KACA
Kayne Anderson Capital Advisors Los Angeles, California $5.22B AUM 17.11% 1-Year Est. Return
DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return
MIM
Merewether Investment Management Dallas, Texas $5.16B AUM 86.81% 1-Year Est. Return
AAI
Aequim Alternative Investments Mill Valley, California $5.16B AUM 9.8% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Maven Securities's Q4 2016 Portfolio in Review

Q4 2016 is the first quarter with a 13F filing on record for Maven Securities, which disclosed 44 positions worth $112M. Its ten largest holdings account for 88% of the portfolio.

Its largest position is HSBC: 908,648 shares worth $33.3M.

By sector, the portfolio is most concentrated in Financials at 34% of assets, followed by Consumer Staples and Consumer Discretionary.

  • Maven Securities's largest Q4 2016 buy was HSBC: 908,648 shares worth $33.3M.
  • Maven Securities's ten largest holdings make up 88% of its $112M portfolio in Q4 2016.
  • Maven Securities disclosed 44 positions in Q4 2016, its first 13F filing on record.

Based on Maven Securities's 13F filing for Q4 2016, filed 13 Feb 2017.